Cytogen, Inc.

KOSDAQ:A217330 Stock Report

Market Cap: ₩96.8b

Cytogen Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Byung-Hee Jeon

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership14.5%
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Analysis Article • Feb 16

Positive Sentiment Still Eludes Cytogen, Inc. (KOSDAQ:217330) Following 29% Share Price Slump

Cytogen, Inc. ( KOSDAQ:217330 ) shares have retraced a considerable 29% in the last month, reversing a fair amount of...
Analysis Article • Dec 09

Market Might Still Lack Some Conviction On Cytogen, Inc. (KOSDAQ:217330) Even After 33% Share Price Boost

Despite an already strong run, Cytogen, Inc. ( KOSDAQ:217330 ) shares have been powering on, with a gain of 33% in the...
Analysis Article • Nov 18

Cytogen (KOSDAQ:217330) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Oct 10

The Market Lifts Cytogen, Inc. (KOSDAQ:217330) Shares 35% But It Can Do More

Cytogen, Inc. ( KOSDAQ:217330 ) shares have had a really impressive month, gaining 35% after a shaky period beforehand...
Analysis Article • Jun 19

Cytogen, Inc.'s (KOSDAQ:217330) Subdued P/S Might Signal An Opportunity

With a price-to-sales (or "P/S") ratio of 5.4x Cytogen, Inc. ( KOSDAQ:217330 ) may be sending very bullish signals at...
Analysis Article • Mar 23

Is Cytogen (KOSDAQ:217330) Weighed On By Its Debt Load?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Jan 25

What You Need To Know About Cytogen, Inc.'s (KOSDAQ:217330) Investor Composition

If you want to know who really controls Cytogen, Inc. ( KOSDAQ:217330 ), then you'll have to look at the makeup of its...
Analysis Article • Dec 03

Is Cytogen (KOSDAQ:217330) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

CEO

Byung-Hee Jeon (67 yo)

no data
Tenure

Mr. Jeon Byung-Hee serves as CEO and Representative Director at Cytogen, Inc.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/13 00:03
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cytogen, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.